FUZIONI POLIPEPTID KOJI SADRŽI DVOJNE JEDINICE PONAVLJANJA CIRKUMSPOROZOITNOG (CS) PROTEINA PLASMODIUM FALCIPARUM

FUZIONI POLIPEPTID KOJI SADRŽI DVOJNE JEDINICE PONAVLJANJA CIRKUMSPOROZOITNOG (CS) PROTEINA PLASMODIUM FALCIPARUM - naznačen time, što je ponavljajuća sekvenca proteina različitog od CS proteina odabrana iz grupe koja obuhvata Gly-Leu-Arg nestrukturne proteine 1 (NS1) virusa influence; 81 N-terminal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YOUNG, J.F, GROSS, M.S, HOCKMEYER, W.T, BALLOUW, R
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FUZIONI POLIPEPTID KOJI SADRŽI DVOJNE JEDINICE PONAVLJANJA CIRKUMSPOROZOITNOG (CS) PROTEINA PLASMODIUM FALCIPARUM - naznačen time, što je ponavljajuća sekvenca proteina različitog od CS proteina odabrana iz grupe koja obuhvata Gly-Leu-Arg nestrukturne proteine 1 (NS1) virusa influence; 81 N-terminalnih amino kiselina iz proizvoda gena otpornosti na tetraciklin (tet86); i 32 N-terminalne amino kiseline iz proizvoda gena otpornosti na tetraciklin (tet32); i što su dvojne jedinice ponavljanja predstavljene formulom: / (Asn-Ala-Asn-Pro)15 (Asn-Val-Asp-Pro)1/n gde je n 1. Prijava sadrži još 8 zavisnih i 1 nezavisan zahtev. A vaccine for protecting mammals against malaria is prepared by a process which comprises combining a polypeptide having four or more tandem repeat units of the Plasmodium falciparum CS protein with a pharmaceutically acceptable carrier.